NCT03682289 2026-04-15
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Recruiting
Clinical Trials
31 trialsNCT04742075 2026-02-27
DOVACC
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Active not recruiting
NCT04065269 2026-02-20
ATARI
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
NCT02726997 2025-12-18
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT03026062 2025-09-19
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03085225 2025-09-04
TRAMUNE
Institut Bergonié
Phase 1 Completed
NCT03267589 2025-07-29
Trial in Patients With Relapsed Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Completed
NCT04019288 2025-06-11
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03277482 2025-05-31
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT03518606 2025-01-15
MOVIE
UNICANCER
Phase 1/2 Completed
NCT05255653 2024-11-29
RAINBO
Leiden University Medical Center
Phase 2/3 Recruiting
NCT02953457 2024-11-19
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
Phase 2 Completed
NCT06680739 2024-11-08
SERPENTINE
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT06650709 2024-10-23
NEOCATS
British Columbia Cancer Agency
Phase 2 Not yet recruiting
NCT03439085 2024-07-09
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03015129 2024-02-06
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03452332 2023-09-13
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02963831 2022-12-22
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT01975831 2022-10-12
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT02431559 2022-10-10
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT04015739 2022-08-17
BOLD
ARCAGY/ GINECO GROUP
Phase 2 Unknown
NCT02764333 2021-11-30
TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02811497 2021-04-01
METADUR
University Health Network, Toronto
Phase 2 Completed
NCT03699449 2021-04-01
An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)
Yonsei University
Phase 2 Unknown
NCT03951415 2021-04-01
DOMEC
Leiden University Medical Center
Phase 2 Unknown
NCT02725489 2021-01-27
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Mary Crowley Medical Research Center
Phase 2 Completed
NCT03430518 2020-08-05
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT04444193 2020-06-23
Dulect2020-2
Shanghai First Maternity and Infant Hospital
Phase NA Unknown
NCT02669914 2018-11-06
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Washington University School of Medicine
Phase 2 Terminated
NCT03283943 2018-07-11
PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.
British Columbia Cancer Agency
Phase 1 Unknown